Opioid Detoxification in Pregnancy: Systematic Review and Meta-Analysis of Perinatal Outcomes

Abstract

Objective We sought to compare the efficacy and safety of detoxification from opioids compared with opioid replacement therapy (ORT) during pregnancy.

Study Design We searched PubMed, Embase, Cochrane Library, and ClinicalTrials.gov from inception to June 2017 for English-language randomized-controlled trials or cohort studies that compared detoxification with ORT. We sought studies with outcomes data on maternal abstinence at the time of delivery, neonatal abstinence syndrome (NAS), stillbirth, and preterm birth (PTB). We calculated pooled relative risks (RRs) with a random-effects model, assessed heterogeneity using the chi-square test for heterogeneity, and quantified heterogeneity using the I ² test. We assessed publication bias using funnel plots and the Harbord test.

Results Three cohort studies met the inclusion criteria; eligible studies included 235 women with opioid use disorder in pregnancy. Maternal detoxification was associated with increased risk of relapse (RR = 1.91; 95% confidence interval [CI] = 1.14–3.21); however, no treatment differences were observed for the rates of NAS (RR = 0.99; 95% CI = 0.38–2.53) or PTB (RR = 0.39; 95% CI = 0.10–1.60).

Conclusion Our findings suggest an increased risk of relapse with detoxification treatment compared with ORT; however, detoxification does not alter the risk of PTB or NAS. Further studies should confirm our findings and explore mechanisms to fight the current opioid epidemic.

Keywords

opioid use disorder - maternal opiate use - neonatal abstinence syndrome - perinatal outcomes

• References

• 1 Center for Behavioral Health Statistics and Quality. Key substance use and mental health indicators in the United States: Results from the 2015 National Survey on Drug Use and Health. NSDUH Series H-51, HHS Publication No. SMA 16–4984. Available at: https://www.samhsa.gov/data/sites/default/files/NSDUH-FFR1-2015/NSDUH-FFR1-2015/NSDUH-FFR1-2015.pdf . Accessed June 1, 2017
• 2 Center for Disease Control and Prevention. Prescription Painkiller Overdoses: A Growing Epidemic, Especially among Women. Atlanta, GA: Centers for Disease Control and Prevention. Available at: http://www.cdc.gov/vitalsigns/prescriptionpainkilleroverdoses/index.html . Accessed June 1, 2017
• 3 Substance Abuse and Mental Health Services Administration. Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings. NSDUH Series H-41, HHS Publication No. SMA 11–4658. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2011. Available at: https://www.samhsa.gov/data/sites/default/files/NSDUHNationalFindingsResults2010-web/2k10ResultsRev/NSDUHresultsRev2010.pdf . Accessed June 1, 2017
• 4 ACOG Committee on Health Care for Underserved Women; American Society of Addiction Medicine. ACOG Committee Opinion No. 524: Opioid abuse, dependence, and addiction in pregnancy. Obstet Gynecol 2012; 119 (05) 1070-1076
• 5 Ross EJ, Graham DL, Money KM, Stanwood GD. Developmental consequences of fetal exposure to drugs: what we know and what we still must learn. Neuropsychopharmacology 2015; 40 (01) 61-87
• 6 Kaltenbach K, Berghella V, Finnegan L. Opioid dependence during pregnancy. Effects and management. Obstet Gynecol Clin North Am 1998; 25 (01) 139-151
• 7 Virginia Department of Health. Pregnancy-associated deaths from drug overdose in Virginia, 1999–2007: a report from the Virginia Maternal Mortality Review Team. Richmond, VA: VDH; 2015. Available at: http://www.vdh.virginia.gov/content/uploads/sites/18/2016/04/Final-Pregnancy-Associated-Deaths-Due-to-Drug-Overdose.pdf . Accessed October 23, 2017
• 8 Maryland Department of Health and Mental Hygiene. Maryland maternal mortality review 2016 annual report. Baltimore, MD: DHMH; 2016. Available at: http://healthymaryland.org/wp-content/uploads/2011/05/MMR_Report_2016_clean-copy_FINAL.pdf . Accessed October 23, 2017
• 9 Zelson C, Lee SJ, Casalino M. Neonatal narcotic addiction. Comparative effects of maternal intake of heroin and methadone. N Engl J Med 1973; 289 (23) 1216-1220
• 10 Kandall SR, Albin S, Lowinson J, Berle B, Eidelman AI, Gartner LM. Differential effects of maternal heroin and methadone use on birthweight. Pediatrics 1976; 58 (05) 681-685
• 11 Kandall SR, Albin S, Gartner LM, Lee KS, Eidelman A, Lowinson J. The narcotic-dependent mother: fetal and neonatal consequences. Early Hum Dev 1977; 1 (02) 159-169
• 12 Lollis CM, Strothers HS, Chitwood DD, McGhee M. Sex, drugs, and HIV: does methadone maintenance reduce drug use and risky sexual behavior?. J Behav Med 2000; 23 (06) 545-557
• 13 Hoegerman G, Schnoll S. Narcotic use in pregnancy. Clin Perinatol 1991; 18 (01) 51-76
• 14 Jones HE, Kaltenbach K, Heil SH. , et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 2010; 363 (24) 2320-2331
• 15 Jones HE, Johnson RE, Jasinski DR. , et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend 2005; 79 (01) 1-10
• 16 Finnegan LP, Kron RE, Connaughton JF, Emich JP. Assessment and treatment of abstinence in the infant of the drug-dependent mother. Int J Clin Pharmacol Biopharm 1975; 12 (1-2): 19-32
• 17 Rementeriá JL, Nunag NN. Narcotic withdrawal in pregnancy: stillbirth incidence with a case report. Am J Obstet Gynecol 1973; 116 (08) 1152-1156
• 18 Haabrekke KJ, Slinning K, Walhovd KB, Wentzel-Larsen T, Moe V. The perinatal outcome of children born to women with substance dependence detoxified in residential treatment during pregnancy. J Addict Dis 2014; 33 (02) 114-123
• 19 Lund IO, Fitzsimons H, Tuten M, Chisolm MS, O'Grady KE, Jones HE. Comparing methadone and buprenorphine maintenance with methadone-assisted withdrawal for the treatment of opioid dependence during pregnancy: maternal and neonatal outcomes. Subst Abuse Rehabil 2012; 3 (Suppl. 01) 17-25
• 20 Jones HE, O'Grady KE, Malfi D, Tuten M. Methadone maintenance vs. methadone taper during pregnancy: maternal and neonatal outcomes. Am J Addict 2008; 17 (05) 372-386
• 21 Dashe JS, Jackson GL, Olscher DA, Zane EH, Wendel Jr GD. Opioid detoxification in pregnancy. Obstet Gynecol 1998; 92 (05) 854-858
• 22 Stewart RD, Nelson DB, Adhikari EH. , et al. The obstetrical and neonatal impact of maternal opioid detoxification in pregnancy. Am J Obstet Gynecol 2013; 209 (03) 267.e1-267.e5
• 23 Maas U, Kattner E, Weingart-Jesse B, Schäfer A, Obladen M. Infrequent neonatal opiate withdrawal following maternal methadone detoxification during pregnancy. J Perinat Med 1990; 18 (02) 111-118
• 24 Smyth BP, Barry J, Keenan E, Ducray K. Lapse and relapse following inpatient treatment of opiate dependence. Ir Med J 2010; 103 (06) 176-179
• 25 Sordo L, Barrio G, Bravo MJ. , et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ 2017; 357: j1550
• 26 Kosten TR, George TP. The neurobiology of opioid dependence: implications for treatment. Sci Pract Perspect 2002; 1 (01) 13-20
• 27 Advisory Council on the Misuse of Drugs. Reducing Drug-Related Deaths. London: Stationery Office; 2000
• 28 Bird SM, Hutchinson SJ. Male drugs-related deaths in the fortnight after release from prison: Scotland, 1996-99. Addiction 2003; 98 (02) 185-190
• 29 Strang J, McCambridge J, Best D. , et al. Loss of tolerance and overdose mortality after inpatient opiate detoxification: follow up study. BMJ 2003; 326 (7396): 959-960